ACAD Q3 2025 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$279M+11.3% YoY

Gross Profit

$257M92.2% margin

Operating Income

$36M12.8% margin

Net Income

$72M25.8% margin

EPS (Diluted)

$0.42

QoQ Revenue Growth

+5.3%

Cash Flow

Operating Cash Flow

$74M

Free Cash Flow

$74M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$413M

Stockholders' Equity

$917M

Cash & Equivalents

$258M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$279M	$250M	+11.3%
Gross Profit	$257M	$232M	+11.0%
Operating Income	$36M	$32M	+13.0%
Net Income	$72M	$33M	+119.1%